molecules-logo

Journal Browser

Journal Browser

Dopamine Receptors and Neurodegeneration

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: closed (30 June 2024) | Viewed by 6935

Special Issue Editor


E-Mail Website
Guest Editor
Department of Psychobiology, Psychology Faculty, Campus of Blasco Ibáñez, University of Valencia, Valencia, Spain
Interests: cognitive neuroscience; dopamine; dopamine transporter; stress; addiction; nanoparticles; neurodegeneration

Special Issue Information

Dear Colleagues,

Dopaminergic dysfunctions can contribute to diverse neuropsychiatric and neurodegenerative disorders, characterized by progressive neuronal loss that leads to degeneration at different levels of the nervous system. Disrupted dopamine (DA) homeostasis, and more specifically dopamine receptor alterations, have been reported in a variety of psychiatric and neurodegenerative disorders.

The present Special Issue provides an excellent opportunity to converge the most updated state of current research studies related to the implication of DA receptors in a variety of neurodegenerative disorders due to the unclear pathogenesis underlying neurodegeneration.

We call for genetic studies as well as basic behavioral and pharmaceutical approaches to help understand better the critical role of each DA receptor in psychopathology to allow the discovery of new treatment approaches for such devastating impacts of neurodegenerative diseases worldwide.

Potential topics include, but are not limited to, the following:

  • Dopamine receptor mechanisms of action on neurodegeneration;
  • The behavioral impacts of DA receptor alterations;
  • Adverse effects of the DA system on neurodegenerative diseases;
  • Molecular basis of DA impairments and their impact on neurodegeneration;
  • Future perspectives for neurodegeneration interventions: dopamine implications;
  • Genetical approaches: implications of DA in neurodegeneration.

Dr. Marta Pardo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • dopamine
  • dopamine receptor
  • neurodegeneration
  • Alzheimer
  • Huntington
  • Parkinson

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

25 pages, 4693 KiB  
Article
Long-Term Impact of Diffuse Traumatic Brain Injury on Neuroinflammation and Catecholaminergic Signaling: Potential Relevance for Parkinson’s Disease Risk
by Ing Chee Wee, Alina Arulsamy, Frances Corrigan and Lyndsey Collins-Praino
Molecules 2024, 29(7), 1470; https://doi.org/10.3390/molecules29071470 - 26 Mar 2024
Cited by 3 | Viewed by 2495
Abstract
Traumatic brain injury (TBI) is associated with an increased risk of developing Parkinson’s disease (PD), though the exact mechanisms remain unclear. TBI triggers acute neuroinflammation and catecholamine dysfunction post-injury, both implicated in PD pathophysiology. The long-term impact on these pathways following TBI, however, [...] Read more.
Traumatic brain injury (TBI) is associated with an increased risk of developing Parkinson’s disease (PD), though the exact mechanisms remain unclear. TBI triggers acute neuroinflammation and catecholamine dysfunction post-injury, both implicated in PD pathophysiology. The long-term impact on these pathways following TBI, however, remains uncertain. In this study, male Sprague-Dawley rats underwent sham surgery or Marmarou’s impact acceleration model to induce varying TBI severities: single mild TBI (mTBI), repetitive mild TBI (rmTBI), or moderate–severe TBI (msTBI). At 12 months post-injury, astrocyte reactivity (GFAP) and microglial levels (IBA1) were assessed in the striatum (STR), substantia nigra (SN), and prefrontal cortex (PFC) using immunohistochemistry. Key enzymes and receptors involved in catecholaminergic transmission were measured via Western blot within the same regions. Minimal changes in these markers were observed, regardless of initial injury severity. Following mTBI, elevated protein levels of dopamine D1 receptors (DRD1) were noted in the PFC, while msTBI resulted in increased alpha-2A adrenoceptors (ADRA2A) in the STR and decreased dopamine beta-hydroxylase (DβH) in the SN. Neuroinflammatory changes were subtle, with a reduced number of GFAP+ cells in the SN following msTBI. However, considering the potential for neurodegenerative outcomes to manifest decades after injury, longer post-injury intervals may be necessary to observe PD-relevant alterations within these systems. Full article
(This article belongs to the Special Issue Dopamine Receptors and Neurodegeneration)
Show Figures

Figure 1

Review

Jump to: Research

30 pages, 2217 KiB  
Review
Advances in Brain Stimulation, Nanomedicine and the Use of Magnetoelectric Nanoparticles: Dopaminergic Alterations and Their Role in Neurodegeneration and Drug Addiction
by Silvia Giménez, Alexandra Millan, Alba Mora-Morell, Noa Ayuso, Isis Gastaldo-Jordán and Marta Pardo
Molecules 2024, 29(15), 3580; https://doi.org/10.3390/molecules29153580 - 29 Jul 2024
Cited by 5 | Viewed by 3367
Abstract
Recent advancements in brain stimulation and nanomedicine have ushered in a new era of therapeutic interventions for psychiatric and neurodegenerative disorders. This review explores the cutting-edge innovations in brain stimulation techniques, including their applications in alleviating symptoms of main neurodegenerative disorders and addiction. [...] Read more.
Recent advancements in brain stimulation and nanomedicine have ushered in a new era of therapeutic interventions for psychiatric and neurodegenerative disorders. This review explores the cutting-edge innovations in brain stimulation techniques, including their applications in alleviating symptoms of main neurodegenerative disorders and addiction. Deep Brain Stimulation (DBS) is an FDA-approved treatment for specific neurodegenerative disorders, including Parkinson’s Disease (PD), and is currently under evaluation for other conditions, such as Alzheimer’s Disease. This technique has facilitated significant advancements in understanding brain electrical circuitry by enabling targeted brain stimulation and providing insights into neural network function and dysfunction. In reviewing DBS studies, this review places particular emphasis on the underlying main neurotransmitter modifications and their specific brain area location, particularly focusing on the dopaminergic system, which plays a critical role in these conditions. Furthermore, this review delves into the groundbreaking developments in nanomedicine, highlighting how nanotechnology can be utilized to target aberrant signaling in neurodegenerative diseases, with a specific focus on the dopaminergic system. The discussion extends to emerging technologies such as magnetoelectric nanoparticles (MENPs), which represent a novel intersection between nanoformulation and brain stimulation approaches. These innovative technologies offer promising avenues for enhancing the precision and effectiveness of treatments by enabling the non-invasive, targeted delivery of therapeutic agents as well as on-site, on-demand stimulation. By integrating insights from recent research and technological advances, this review aims to provide a comprehensive understanding of how brain stimulation and nanomedicine can be synergistically applied to address complex neuropsychiatric and neurodegenerative disorders, paving the way for future therapeutic strategies. Full article
(This article belongs to the Special Issue Dopamine Receptors and Neurodegeneration)
Show Figures

Figure 1

Back to TopTop